

Revised Draft Agenda
Biocides Working Group Meeting II-2020
2-12 June 2020

WG-II-2020 meetings are held as virtual meetings via WebEx

The time is indicated in Helsinki time.

Monday 8 June	10:00-13:00	APCP WG
	14:00-18:00	
Tuesday 9 June	10:00-13:00	TOX WG
	14:00-17:00	
Wednesday 10 June	10:00-13:00	TOX WG
	14:00-17:00	
Thursday 11 June	10:00-13:00	TOX WG
	14:00-17:00	
Tuesday 2 June	10:00-13:00	EFF WG
	14:00-18:00	
Thursday 4 June	10:00-13:00	EFF WG
	14:00-18:00	
Wednesday 10 June	10:30-13:00	EFF WG
	14:00-18:00	
Thursday 11 June	10:00-13:00	ENV WG
	14:00-18:00	
Friday 12 June	10:00-13:00	ENV WG
	14:00-16:00	

<p>8.2</p>	<p>Hydrogen peroxide released from sodium percarbonate Early working group discussion PT 02 and 03 Meeting documents: <i>WG II 2020_APCP_8-2</i></p> <p style="text-align: right;"><i>For discussion</i></p>	<p>FI</p>
<p>Item 9 – AOB</p>		

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-I-2020		
<ul style="list-style-type: none"> • WG-I-2020_TOX_6-1 • WG-I-2020_TOX_6-2 • WG-I-2020_TOX_6-3 • WG-I-2020_TOX_6-4 • WG-I-2020_TOX_6-5 • WG-I-2020_TOX_6-6 • WG-I-2020_TOX_6-7 • WG-I-2020_TOX_7-1 • WG-I-2020_TOX_7-2 • WG-I-2020_TOX_7-3 • WG-I-2020_TOX_Minutes 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Alpha-bromodialone PT 14 Meeting documents: <i>WGII2020_TOX_6-1</i>	FR <i>For agreement</i>
6.2	Chlorine dioxide – Genotoxicity assessment PT 9 Meeting documents: <i>WGII2020_TOX_6-2</i>	DE <i>For agreement</i>
6.3	ADBAC/BKC – ED assessment PT 03, 04 Meeting document: <i>WGII2020_TOX_6-3</i>	IT <i>For agreement</i>
6.4	DDAC – ED assessment PT 03, 04 Meeting document: <i>WGII2020_TOX_6-4</i>	IT <i>For agreement</i>

Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product containing clothianidin and pyriproxyfen PT 18 (BC-HS027052-37) Meeting document: <i>WGII2020_TOX_7-1</i> <i>For agreement</i>	NL
7.2	Harmonisation of assessment among applications for UA containing lactic acid Closed session for MSCAs only Meeting document: <i>WGII2020_TOX_7-2</i> <i>For agreement</i>	FR
Item 8 - Technical and guidance related issues		Presenter
8.1	Update on guidance development Meeting document: <i>WGII2020_TOX_8-1</i> <i>For discussion</i>	SECR
8.2	Quantitative risk characterisation for sensitisers Meeting document: <i>WGII2020_TOX_8-2</i> <i>For discussion</i>	SECR
8.3	Revising ECHA guidance Vol III Part A Meeting document: <i>WGII2020_TOX_8-3</i> <i>For discussion</i>	SECR
8.4	Revising the WG recommendation on in situ generated substances Meeting document: <i>WGII2020_TOX_8-4</i> <i>For discussion</i>	SECR
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGII2020_TOX_9-1</i> <i>For discussion</i>	SECR

Efficacy Working Group		
Chair: Katarzyna Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-I-2020		
<ul style="list-style-type: none"> • <i>WG-I-2020_EFF_6-1</i> • <i>WG-I-2020_EFF_6-2</i> • <i>WG-I-2020_EFF_6-3</i> • <i>WG-I-2020_EFF_7-1</i> • <i>WG-I-2020_EFF_7-2</i> • <i>WG-I-2020_EFF_7-3</i> • <i>WG-I-2020_EFF_Minutes</i> 		<i>For agreement</i>
Item 6 – Discussion of Active Substances		eCA
6.1	alpha-bromodialone PT 14 Meeting document: <i>WGII2020_EFF_6-1</i>	FR <i>For agreement</i>
6.2.	Early WG on Free radicals generated in situ from ambient water catalysed by transition metal oxides PT 2,4,9,21 Meeting document: <i>WGII2020_EFF_6-2</i>	AT <i>For agreement</i>
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product containing clothianidin and pyriproxyfen PT 18 (BC-HS027052-37) Meeting document: <i>WGII2020_EFF_7-1</i>	NL <i>For agreement</i>

Item 8 - Technical and guidance related issues		
8.1	Vol. II, Parts B+C – PT19 Meeting documents: <i>WGII2020_EFF_8-1a – Introduction</i> <i>WGII2020_EFF_8-1b – Biting midges;</i> <i>For discussion</i>	DE DK
8.2	Vol. II, Parts B+C – PT12 Meeting document: <i>WGII2020_EFF_8-2</i> <i>For discussion</i>	FR
8.3	Vol. II, Parts B+C – Appendix 4 Meeting document: <i>WGII2020_EFF_8-3</i> <i>For discussion</i>	ECHA
8.4	Hard surfaces disinfection – contact time and application rate Meeting document: <i>WGII2020_EFF_8-4</i> <i>For discussion</i>	NL
8.5	TAB proposals Meeting document: <i>WGII2020_EFF_8-5</i> <i>For discussion</i>	NL FI DE
Item 9 – AOB		
9.1	Other information & lessons learned Meeting document: <i>WGII2020_EFF_9-1</i> <i>For information</i>	ECHA

Environment Working Group Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-I-2020 <ul style="list-style-type: none"> • WG-I-2020_ENV_6-1 • WG-I-2020_ENV_6-2 • WG-I-2020_ENV_6-3 • WG-I-2020_ENV_6-4 • WG-I-2020_ENV_6-5 • WG-I-2020_ENV_6-7 • WG-I-2020_ENV_6-8 • WG-I-2020_ENV_7-1 • WG-I-2020_ENV_7-2 • WG-I-2020_ENV_7-3 • WG-I-2020_ENV_7-4 • WG-I-2020_ENV_General_minutes • WG-I-2020 Part B 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	alpha-bromodialone PT 14 Meeting document: <i>WGII2020_ENV_6-1</i>	FR <i>For agreement</i>
6.2	ADBAC/BKC – ED assessment PT 03, 04 Meeting document: <i>WGII2020_ENV_6-2</i>	IT <i>For agreement</i>
6.3	DDAC – ED assessment PT 03, 04 Meeting document: <i>WGII2020_ENV_6-3</i>	IT <i>For agreement</i>

Item 7 - Discussion of Products		eCA
7.1	UA for product containing clothianidin and pyriproxyfen PT 18 (BC-HS027052-37) Meeting document: <i>WGII2020_ENV_7-1</i> <i>For agreement</i>	NL
7.2	Early WG: UA for product family containing CMIT/MIT – selected items PT 02, 04, 06, 11, 12, 13 (BC-CY032700-28) Meeting document: <i>WGII2020_ENV_7-2</i> <i>For agreement</i>	FR
7.3	PNEC_{soil} derivation for cyromazine containing biocidal products (PT 18) Follow up e-consultation of May 2020 Meeting document: <i>WGII2020_ENV_7-3</i> <i>For agreement</i>	DE
7.4	Harmonised assessment of groundwater concentrations for lactic acid in product authorisations Follow up e-consultation of Feb. 2020 Meeting document: <i>WGII2020_ENV_7-4</i> <i>For agreement</i>	FR
7.5	Harmonisation of environmental fate endpoints for an SoC Follow up e-consultation of May 2020 Meeting document: <i>WGII2020_ENV_7-5</i> <i>For agreement</i>	DE
Item 8 – Technical and guidance related issues (General WebEx option for WG)		Presenter
8.1	Overview on guidance Meeting document: <i>WGI2020_ENV_8-1</i> <i>For information</i>	SECR
8.2	Open questions regarding PT 18 (e.g. treatment areas) Followup of e-consultations Q1/Q2 2020 Meeting document: <i>WGI2020_ENV_8-2</i> <i>For agreement</i>	NL/FR
8.3	Organic carbon normalisation Followup WG-V-2019 Meeting document: <i>WGI2020_ENV_8-3</i> <i>For agreement</i>	DE
8.4	Open TAB entries after TAB v2.1 commenting Meeting document: <i>WGI2020_ENV_8-4</i> <i>For agreement</i>	SECR

Item 9 – AOB (General WebEx option for WG)		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGII2020_ENV_9-1</i> <i>For information</i>	SECR
9.2	Update on EUSES & Workshop on Meeting document: <i>WGII2020_ENV_9-2</i> <i>For information</i>	SECR
9.3	Report on follow up actions of the active substance action plan (ASAP) Meeting document: <i>WGII2020_ENV_9-3</i> <i>For information</i>	SECR

oOo